Barclays PLC Schedule 13G passive stakes

Barclays PLC has disclosed beneficial ownership of 273,125 shares, representing 6.74% of the outstanding common stock in Rising Dragon Acquisition Co.

Barclays PLC has filed a Schedule 13G, disclosing a minimal beneficial ownership of 20 shares in Reviva Pharmaceuticals, representing 0.00% of the class.

Barclays PLC has filed a Schedule 13G, reporting a beneficial ownership of 0.17% in Tavia Acquisition Corp's common stock as of June 30, 2026.

Barclays PLC has updated its Schedule 13G filing to reflect a 0.04% beneficial ownership in Range Capital Acquisition Co. as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, reporting a 4.54% beneficial ownership stake in Madison Square Garden Entertainment Corp. as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 4.13% of Newhold Investment Corp II-A's common stock as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 3.17% of Zentalis Pharmaceuticals Inc. common stock as of June 30, 2026.

Barclays PLC has updated its beneficial ownership filing for Everspin Technologies Inc., reporting a 1.89% stake as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, reporting a 1.72% beneficial ownership in Bel Fuse Inc.'s common stock as of June 30, 2026.

Barclays PLC has reported beneficial ownership of 1,231,531 shares, representing 5.97% of the class, in Axiom Intelligence-CL A as of June 30, 2026.

Barclays PLC has updated its beneficial ownership filing for Penumbra Inc., reporting a 5.95% stake as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 5.00% of ROMAN DBDR ACQUISITION CORP's common stock as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 4.97% of LAUNCH TWO ACQUISITION- CL A common stock as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, indicating a beneficial ownership of 4.91% in Lakeshore Acquisition III Co as of June 30, 2026.

Barclays PLC has disclosed a beneficial ownership of 6.99% in Oaktree Acquisition Corp I-A's common stock as of June 30, 2026.

Barclays PLC has disclosed beneficial ownership of 6.81% of CH4 Natural Solutions' common stock as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, reporting a beneficial ownership of 6.30% in Liberty Broadband-A common stock as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 5.99% of Cartesian Therapeutics Inc. common stock as of June 30, 2026.

Barclays PLC has filed a Schedule 13G, reporting beneficial ownership of 8.43% of Office Properties Income REIT.

Barclays PLC has disclosed beneficial ownership of 7.84% of Forward Air Corp's common stock as of June 30, 2026.

Barclays PLC has disclosed beneficial ownership of 7.00% of ProCap Acquisition Corp's common stock, holding 1,780,100 shares.

Barclays PLC has filed a Schedule 13G, disclosing beneficial ownership of 3,900 shares, representing 0.01% of the outstanding common stock of Crane Harbor Acqu Corp - A.

Barclays PLC has reported beneficial ownership of 7.00% of Centurion Acquisition Corp's common stock as of March 31, 2026.

Barclays PLC has disclosed a beneficial ownership of 1,122,625 shares in Range Capital Acquisition Co, representing a 7% stake in the entity.

Barclays PLC disclosed a new passive investment in Talkspace Inc, totaling over 2.5 million shares and representing a 6.105% ownership stake.

Barclays PLC has disclosed a 5.30% passive ownership stake in JELD-WEN Holding Inc, totaling over 4.5 million shares.

Barclays PLC has filed a Schedule 13G reporting a 5.46% beneficial ownership stake in Tavia Acquisition Corp.

Barclays PLC has filed a Schedule 13G reporting a 5.54% beneficial ownership stake in Masimo Corp as of March 31, 2026.

Barclays PLC has filed a Schedule 13G reporting a 5.65% beneficial ownership stake in Amicus Therapeutics Inc.

Barclays PLC has filed a Schedule 13G reporting a 5.69% beneficial ownership stake in Star Holdings common stock.